Company
COMPASS Pathways plc
Headquarters: Altrincham, United Kingdom
Employees: 116
CEO: Mr. George Jay Goldsmith
Market Cap
$594.8 Million
USD as of Jan. 1, 2024
COMPASS Pathways plc Categories
United Kingdom Healthcare Medical Care FacilitiesUnited Kingdom Healthcare United Kingdom Medical Care Facilities
Top Competitors by Market Capitalization
Industry: Medical Care Facilities
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $586.39 B |
| UnitedHealth Group | $504.47 B |
| Novo Nordisk | $461.52 B |
| Johnson & Johnson | $387.50 B |
| Merck | $296.51 B |
Detailed Description
COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.
Top 1-year algo backtest: +298.72%
$10,000 in April 2023 would now be $39,872 by following this algorithm daily at market close.
Boost your stocks returns with Disfold AI... Now!
Try Disfold AI for FREE
Stocks & Indices
COMPASS Pathways plc has the following listings and related stock indices.
Stock: NASDAQ: CMPS wb_incandescent
Stock: FSX: 5Y6 wb_incandescent